ANIP FY 2022 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

FY 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$316M+46.4% YoY

Gross Profit

$178M56.1% margin

Operating Income

-$35M-11.2% margin

Net Income

-$48M-15.1% margin

EPS (Diluted)

$-3.05

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$48M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$760M

Total Liabilities

$422M

Stockholders' Equity

$339M

Cash & Equivalents

$48M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$316M	$216M	+46.4%
Gross Profit	$178M	$116M	+53.7%
Operating Income	-$35M	-$40M	+11.3%
Net Income	-$48M	-$43M	-12.4%